Minerva Neurosciences (NASDAQ:NERV) Stock Price Crosses Below 200-Day Moving Average – Here’s What Happened

Minerva Neurosciences, Inc. (NASDAQ:NERV) shares passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $2.50 and traded as low as $2.20. Minerva Neurosciences shares last traded at $2.38, with a volume of 53,909 shares changing hands.

Analysts Set New Price Targets

NERV has been the topic of several recent research reports. StockNews.com initiated coverage on shares of Minerva Neurosciences in a research note on Thursday. They issued a “sell” rating on the stock. HC Wainwright reissued a “neutral” rating and issued a $5.00 price objective on shares of Minerva Neurosciences in a research note on Wednesday, November 6th.

Minerva Neurosciences Trading Up 3.5 %

The firm has a market capitalization of $16.64 million, a price-to-earnings ratio of -5.41 and a beta of 0.12. The stock’s 50 day moving average price is $2.24 and its two-hundred day moving average price is $2.50.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.